Cytomegalovirus (CMV) Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Denmark, China, Canada, India - Size and Forecast 2024-2028

Cytomegalovirus (CMV) Therapeutics Market Size 2024-2028

The cytomegalovirus (CMV) therapeutics market size is forecast to increase by USD 270.4 million at a CAGR of 4.5% between 2023 and 2028.

• The market is experiencing significant growth due to the increasing prevalence of CMV infection, particularly among immunocompromised individuals and those with weakened immune systems. CMV infection can lead to various health issues, including fatigue, muscle aches, fever, and in severe cases, CMV mononucleosis and pneumonitis. Prevention remains a key focus in the market, with efforts underway to develop vaccines and improve patient adherence to antiviral medications. Furthermore, the need for early and accurate medical diagnostics, especially during pregnancy, is crucial to prevent complications. Additionally, the reformulation of existing drugs is a notable trend, aiming to enhance their efficacy and reduce side effects. However, challenges persist, such as the complex nature of CMV and the need for personalized treatment approaches based on individual patient profiles. Prognosis and effective management of CMV infection remain crucial for improving patient outcomes and reducing the long-term health consequences associated with this virus.

What will be the Size of the Cytomegalovirus (CMV) Therapeutics Market During the Forecast Period?

Request Free Sample

• The market encompasses the development, approval, and commercialization of drugs intended for the treatment, prevention, and management of CMV infections. This market is driven by the significant global burden of CMV infections, which can lead to various health complications such as hearing loss, developmental issues, and compromised immune function in individuals with congenital CMV or those with compromised immune systems, including transplant recipients and pregnant women. Symptoms of CMV infection can range from mild, such as fatigue and muscle aches, to severe, including pneumonitis, retinitis, gastritis, and encephalitis. Diagnosis is typically made through various methods, including blood tests, and treatment options include antiviral therapies for both primary infections and reactivation.

• Moreover, diagnosis of CMV infection is typically done through Blood tests, and treatment options include antiviral medications for primary infections and prevention strategies for reactivation infections. Prevention measures include maintaining a healthy immune system and avoiding contact with infected individuals. The prognosis for CMV infection varies depending on the severity of the infection and the individual's immune status. In immunocompetent individuals, the virus may cause no symptoms or mild illness, while in immunocompromised individuals, the infection can lead to serious complications and even death. Despite the availability of diagnostic and treatment options, there is a significant unmet need for effective therapeutics to prevent and treat CMV infections, particularly in high-risk populations such as transplant recipients and pregnant women.

• Furthermore, the market is expected to grow due to the increasing prevalence of CMV infections and the need for more effective treatment options. The market for CMV therapeutics is driven by the increasing number of individuals with compromised immune systems due to factors such as aging, HIV, and transplantation. Additionally, the growing awareness of the importance of preventing and treating CMV infections in pregnant women is expected to fuel market growth.

How is this Cytomegalovirus (CMV) Therapeutics Industry segmented and which is the largest segment?

The cytomegalovirus (CMV) therapeutics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

• Route Of Administration
  • Oral
  • Parenteral
  • Others
• Geography
  • North America
    • Canada
    • US
  • Europe
    • Denmark
  • Asia
    • China
    • India
  • Rest of World (ROW)

By Route Of Administration Insights

• The oral segment is estimated to witness significant growth during the forecast period.

Get a glance at the market report of share of various segments Request Free Sample

The Oral segment was valued at USD 411.80 million in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

• North America is estimated to contribute 37% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market size of various regions, Request Free Sample

Cytomegalovirus (CMV), a member of the Herpesviridae family, is a common viral infection affecting individuals with compromised immune systems, including newborns, transplant recipients, and those with HIV or AIDS. CMV can lead to various health issues, such as hearing loss, developmental issues, and vision impairment, particularly in congenital cases. Symptoms of CMV infection include fatigue, muscle aches, fever, and specific conditions like pneumonitis, retinitis, gastritis, and encephalitis. Diagnosis is typically through laboratory tests, such as blood, urine, or saliva tests, or tissue samples. Treatment involves antiviral medications that inhibit virus reproduction. Prevention includes maintaining a healthy immune system and avoiding contact with infected body fluids.

The global CMV therapeutics market is significant due to the high prevalence of CMV infections, particularly in North America, where approximately half of the adult population under the age of 40 carries the virus. If left untreated, CMV can lead to serious complications.

Market Dynamics

Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

What are the key market drivers leading to the rise In the adoption of Cytomegalovirus (CMV) Therapeutics Industry?

Growing risk factors for CMV is the key driver of the market.

• The global market for CMV therapeutics is driven by the significant prevalence of this herpes virus, which affects approximately 37 million people worldwide. Reduction in immunity, a common outcome of CMV infection, increases the risk for various indications such as hearing loss, developmental issues, and compromised immune systems in transplant recipients and those with HIV or AIDS. Transmission primarily occurs through the exchange of bodily fluids. Despite a decreasing incidence rate, the high prevalence and limited approved therapies create a substantial unmet need In the market. Symptoms of CMV infection can include fatigue, muscle aches, fever, and specific conditions like CMV pneumonitis, retinitis, gastritis, and encephalitis.
• Despite a decrease in new infections, the high prevalence of CMV, estimated to be around 37 million people worldwide, creates a substantial unmet need in the market. Amniocentesis and ultrasound are commonly used diagnostic tools for identifying CMV infections in babies before birth. The risk of CMV transmission from mother to baby during pregnancy can lead to severe health complications, making the development of effective therapeutics a priority.

What are the market trends shaping the Cytomegalovirus (CMV) Therapeutics Industry?

Reformulation of drugs is the upcoming market trend.

• The market is experiencing growth due to the development of new formulations of approved drugs. These drugs are administered either orally or intravenously to provide effective treatment options for patients. For instance, oral medications require patients to take one tablet daily, while intravenous administration involves daily infusions through a line. Vitrasert, offered by Bausch Health, is a drug approved for treating CMV in patients with compromised immune systems, such as those with HIV/AIDS. Symptoms of CMV infection include fatigue, muscle aches, fever, and various complications like CMV pneumonitis, retinitis, gastritis, and encephalitis. Diagnosis is typically done through laboratory tests, including blood, urine, and saliva tests, as well as tissue samples.
• Prevention includes maintaining a healthy immune system and avoiding transmission through body fluids. The prognosis for individuals with a healthy immune system is generally good, but those who are immunocompromised, such as transplant recipients, pregnant women, and newborns, face a higher risk of severe complications. Antiviral medications are the primary treatment for CMV infection, both during primary infection and reactivation. Monitoring is essential for individuals at high risk, including pregnant women and transplant recipients, to ensure early detection and effective treatment.

What challenges does the Cytomegalovirus (CMV) Therapeutics Industry face during its growth?

Low patient adherence is a key challenge affecting the industry growth.

• The market faces a significant challenge due to the limited number of approved therapies for this herpes virus. Currently, only eight treatments are available, with two being generics for managing CMV infections. These therapies, while effective, come with high costs and prolonged treatment durations. For instance, PREVYMIS, a recently approved antiviral medication, requires patients to use the drug for up to 100 days. The cost of oral PREVYMIS is approximately USD 195 per day, while intravenously administered PREVYMIS costs around USD 270 In the US. This high cost is a barrier for many patients, particularly those with compromised immune systems, such as transplant recipients, individuals with HIV/AIDS, and pregnant women at risk for congenital CMV.
• Symptoms of CMV infection include fatigue, muscle aches, fever, and various complications, such as CMV pneumonitis, retinitis, gastritis, and encephalitis. Diagnosis involves laboratory tests using body fluids, such as blood, urine, or saliva, and tissue samples. Prevention includes maintaining a healthy immune system and avoiding transmission through body fluids. The prognosis for individuals with weakened immune systems is poorer than for those with healthy immune systems. New CMV infections can lead to developmental issues and hearing loss in newborns, making prenatal testing essential. Tests include amniocentesis, amniotic fluid analysis, and ultrasound. Antiviral medications are the primary treatment for CMV infections, and vaccines are under development.
• Monitoring is crucial for individuals at risk, particularly transplant recipients and pregnant women.

Exclusive Customer Landscape

The cytomegalovirus (CMV) therapeutics market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the cytomegalovirus (CMV) therapeutics market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, cytomegalovirus (CMV) therapeutics market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence In the industry

The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• Astellas Pharma Inc.
• AstraZeneca Plc
• Bausch Lomb Corp.
• Chimerix Inc.
• Clinigen Group Plc
• Exela Pharma Sciences LLC
• F. Hoffmann La Roche Ltd.
• Fortress Biotech Inc.
• Fresenius SE and Co. KGaA
• Genentech Inc.
• Gilead Sciences Inc.
• Merck and Co. Inc.
• ProBioGen AG
• Synklino AS
• Takeda Pharmaceutical Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
• Thermo Fisher Scientific Inc.
• UbiVac
• VBI Vaccines Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Research Analyst Overview

Cytomegalovirus (CMV), a member of the herpesviridae family, is a common infectious agent that can cause significant morbidity and mortality, particularly in individuals with compromised immune systems. This virus can lead to various clinical manifestations, ranging from asymptomatic infection to severe disease, including congenital CMV in unborn children and serious complications in transplant recipients, HIV/AIDS patients, and pregnant women. The global CMV therapeutics market is driven by the increasing prevalence of the virus and the growing demand for effective treatments to manage its complications. The market is characterized by ongoing research and development efforts to create novel therapeutic options that can address the diverse clinical needs of the patient population.

The impact of CMV infection can be particularly significant during pregnancy, where it can lead to developmental issues and hearing loss In the unborn child. Congenital CMV infection can result in long-term health consequences, including growth problems, developmental delays, and neurological disorders. In transplant recipients and individuals with weakened immune systems, CMV can cause a range of symptoms, including fatigue, muscle aches, fever, and organ-specific complications such as pneumonitis, retinitis, gastritis, and encephalitis. The diagnosis of CMV infection typically involves laboratory tests, such as blood tests, urine tests, and saliva tests, which can detect the presence of CMV antibodies or the virus itself in body fluids.

Tissue samples may also be taken for further analysis. The prognosis for individuals with CMV infection depends on the severity of the disease and the underlying health condition of the patient. Prevention strategies for CMV infection include maintaining a healthy immune system and avoiding contact with infected body fluids. For high-risk individuals, such as pregnant women and transplant recipients, antiviral medications may be prescribed to prevent new CMV infection or reactivation of the virus. The global CMV therapeutics market is expected to grow significantly In the coming years, driven by the increasing burden of the disease and the need for effective treatments to manage its complications.

The market is characterized by ongoing research and development efforts to create novel therapeutic options that can address the diverse clinical needs of the patient population. Despite the advances in CMV therapeutics, there remain significant challenges in treating this virus, particularly in individuals with weakened immune systems. The development of new antiviral medications and vaccines is an area of active research, with the potential to significantly impact the CMV therapeutics market In the coming years. Cytomegalovirus (CMV) is a significant health concern, particularly for individuals with compromised immune systems. The global CMV therapeutics market is driven by the increasing prevalence of the virus and the growing demand for effective treatments to manage its complications.

Furthermore, prevention includes maintaining a healthy immune system and avoiding contact with the body fluids of infected individuals. For instance, patients may be prescribed a daily oral tablet or an intravenous infusion once a day. The market for CMV therapeutics is witnessing growth as companies strive to improve treatment options and ensure drug efficacy. Prenatal tests, such as amniocentesis and ultrasound, can detect CMV infection in unborn children, allowing for early intervention. The prognosis for CMV infection varies depending on the individual's health status and the severity of the infection. Healthy immune systems can effectively fight off the virus, while weakened immunity can lead to more serious complications. Regular monitoring and medication are essential for managing CMV infection in immunocompromised individuals and preventing transmission to newborns during delivery.

Request Free Sample

What are the Key Data Covered in this Cytomegalovirus (CMV) Therapeutics Market Research and Growth Report?

• CAGR of the Cytomegalovirus (CMV) Therapeutics industry during the forecast period
• Detailed information on factors that will drive the growth and forecasting between 2024 and 2028
• Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
• Accurate predictions about upcoming growth and trends and changes in consumer behaviour
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market's competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the cytomegalovirus (CMV) therapeutics market growth of industry companies

We can help! Our analysts can customize this cytomegalovirus (CMV) therapeutics market research report to meet your requirements.

Get in touch